Arrowhead Pharmaceuticals (NASDAQ:ARWR) – Analysts at Jefferies Group cut their Q3 2018 earnings estimates for Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, May 9th, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft now expects that the biotechnology company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.18). Jefferies Group currently has a “Buy” rating and a $10.00 price objective on the stock. Jefferies Group also issued estimates for Arrowhead Pharmaceuticals’ Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.76) EPS and FY2021 earnings at ($0.08) EPS.
ARWR has been the topic of several other reports. Cantor Fitzgerald set a $5.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “neutral” rating in a research report on Monday, February 12th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 19th. Piper Jaffray Companies lifted their target price on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. Finally, Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Arrowhead Pharmaceuticals has an average rating of “Buy” and an average price target of $9.00.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%.
A number of hedge funds have recently bought and sold shares of ARWR. Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth approximately $100,000. Vanguard Capital Wealth Advisors bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $119,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $123,000. Jane Street Group LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $130,000. Finally, Trexquant Investment LP bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth approximately $139,000. 44.58% of the stock is owned by institutional investors.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $8.00, for a total value of $160,000.00. Following the completion of the sale, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at $2,646,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 300,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares of the company’s stock, valued at $16,307,282.27. The disclosure for this sale can be found here. Insiders have sold 465,000 shares of company stock worth $3,432,350 over the last ninety days. 4.60% of the stock is currently owned by insiders.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.